299 related articles for article (PubMed ID: 17055622)
1. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.
Anh DD; Canh DG; Lopez AL; Thiem VD; Long PT; Son NH; Deen J; von Seidlein L; Carbis R; Han SH; Shin SH; Attridge S; Holmgren J; Clemens J
Vaccine; 2007 Jan; 25(6):1149-55. PubMed ID: 17055622
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.
Desai SN; Akalu Z; Teshome S; Teferi M; Yamuah L; Kim DR; Yang JS; Hussein J; Park JY; Jang MS; Mesganaw C; Taye H; Beyene D; Bedru A; Singh AP; Wierzba TF; Aseffa A
Am J Trop Med Hyg; 2015 Sep; 93(3):527-533. PubMed ID: 26078323
[TBL] [Abstract][Full Text] [Related]
5. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.
Charles RC; Hilaire IJ; Mayo-Smith LM; Teng JE; Jerome JG; Franke MF; Saha A; Yu Y; Kováč P; Calderwood SB; Ryan ET; LaRocque RC; Almazor CP; Qadri F; Ivers LC; Harris JB
PLoS Negl Trop Dis; 2014 May; 8(5):e2828. PubMed ID: 24786645
[TBL] [Abstract][Full Text] [Related]
7. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
[TBL] [Abstract][Full Text] [Related]
8. Questionable merits of the field trial of an oral killed whole cell cholera vaccine in Vietnam during 1998-2003.
Kabir S
Vaccine; 2007 Feb; 25(8):1353-4. PubMed ID: 17049687
[No Abstract] [Full Text] [Related]
9. Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.
Capeding MRZ; Gonzales MLAM; Dhingra MS; D'Cor NA; Midde VJ; Patnaik BN; Thollot Y; Desauziers E
Hum Vaccin Immunother; 2017 Oct; 13(10):2232-2239. PubMed ID: 28910563
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.
Sur D; Lopez AL; Kanungo S; Paisley A; Manna B; Ali M; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Rao R; Nguyen TV; Donner A; Ganguly NK; Nair GB; Bhattacharya SK; Clemens JD
Lancet; 2009 Nov; 374(9702):1694-702. PubMed ID: 19819004
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.
Mahalanabis D; Lopez AL; Sur D; Deen J; Manna B; Kanungo S; von Seidlein L; Carbis R; Han SH; Shin SH; Attridge S; Rao R; Holmgren J; Clemens J; Bhattacharya SK
PLoS One; 2008 Jun; 3(6):e2323. PubMed ID: 18523643
[TBL] [Abstract][Full Text] [Related]
12. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.
Bhattacharya SK; Sur D; Ali M; Kanungo S; You YA; Manna B; Sah B; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Dhingra MS; Donner A; Nair GB; Lopez AL; Wierzba TF; Clemens JD
Lancet Infect Dis; 2013 Dec; 13(12):1050-6. PubMed ID: 24140390
[TBL] [Abstract][Full Text] [Related]
13. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial.
Kanungo S; Paisley A; Lopez AL; Bhattacharya M; Manna B; Kim DR; Han SH; Attridge S; Carbis R; Rao R; Holmgren J; Clemens JD; Sur D
Vaccine; 2009 Nov; 27(49):6887-93. PubMed ID: 19761838
[TBL] [Abstract][Full Text] [Related]
14. Vibrio cholerae: lessons for mucosal vaccine design.
Bishop AL; Camilli A
Expert Rev Vaccines; 2011 Jan; 10(1):79-94. PubMed ID: 21162623
[TBL] [Abstract][Full Text] [Related]
15. Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh.
Akter A; Dash P; Aktar A; Jahan SR; Afrin S; Basher SR; Hakim A; Lisa AK; Chowdhury F; Khan AI; Xu P; Charles RC; Kelly M; Kováč P; Harris JB; Bhuiyan TR; Calderwood SB; Ryan ET; Qadri F
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007634. PubMed ID: 31369553
[TBL] [Abstract][Full Text] [Related]
16. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
Baik YO; Choi SK; Olveda RM; Espos RA; Ligsay AD; Montellano MB; Yeam JS; Yang JS; Park JY; Kim DR; Desai SN; Singh AP; Kim IY; Kim CW; Park SN
Vaccine; 2015 Nov; 33(46):6360-5. PubMed ID: 26348402
[TBL] [Abstract][Full Text] [Related]
17. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
Kamruzzaman M; Kelly M; Charles RC; Harris JB; Calderwood SB; Akter A; Biswas R; Kaisar MH; Bhuiyan TR; Ivers LC; Ternier R; Jerome JG; Pfister HB; Lu X; Soliman SE; Ruttens B; Saksena R; Mečárová J; Čížová A; Qadri F; Bystrický S; Kováč P; Xu P; Ryan ET
mSphere; 2021 Aug; 6(4):e0011421. PubMed ID: 34232076
[TBL] [Abstract][Full Text] [Related]
18. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
20. Cholera vaccine: new preventive tool for endemic countries.
Verma R; Khanna P; Chawla S
Hum Vaccin Immunother; 2012 May; 8(5):682-4. PubMed ID: 22634452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
